Scott Oh1, Reza Ronaghi2, Tao He2, Catherine Oberg2, Colleen Channick2, Irawan Susanto2, Mathew Carroll3, S Sam Weigt4, David Sayah4, Tamas Dolinay4, Augustine Chung4, Gregory Fishbein5, Joseph P Lynch4, John A Belperio4. 1. Section of Interventional Pulmonology, USA; Department of Medicine, USA; Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, USA. Electronic address: ssoh@mednet.ucla.edu. 2. Section of Interventional Pulmonology, USA; Department of Medicine, USA; Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, USA. 3. Department of Medicine, USA. 4. Department of Medicine, USA; Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, USA. 5. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Abstract
INTRODUCTION: Transbronchial lung cryobiopsy (TBLC) has emerged as a promising alternative to surgical lung biopsy for the diagnosis of interstitial lung disease. However, uncertainty remains regarding its overall complications due to a lack of procedural standardization including the size of cryoprobe utilized. METHODS: This is a prospective cohort study of a protocolized transbronchial cryobiopsy program utilizing a 2.4 mm cryoprobe. 201 consecutive subjects were enrolled at a single academic center. RESULTS: The average biopsy size was 106.2 ± 39.3 mm2. Complications included a total pneumothorax rate of 4.9% with 3.5% undergoing chest tube placement. Severe bleeding defined by the Nashville Working Group occurred in 0.5% of cases. There were no deaths at 30-days. DISCUSSION: A protocolized transbronchial cryobiopsy program utilizing a 2.4 mm cryoprobe in can achieve a high diagnostic yield with a favorable safety profile. Published by Elsevier Ltd.
INTRODUCTION: Transbronchial lung cryobiopsy (TBLC) has emerged as a promising alternative to surgical lung biopsy for the diagnosis of interstitial lung disease. However, uncertainty remains regarding its overall complications due to a lack of procedural standardization including the size of cryoprobe utilized. METHODS: This is a prospective cohort study of a protocolized transbronchial cryobiopsy program utilizing a 2.4 mm cryoprobe. 201 consecutive subjects were enrolled at a single academic center. RESULTS: The average biopsy size was 106.2 ± 39.3 mm2. Complications included a total pneumothorax rate of 4.9% with 3.5% undergoing chest tube placement. Severe bleeding defined by the Nashville Working Group occurred in 0.5% of cases. There were no deaths at 30-days. DISCUSSION: A protocolized transbronchial cryobiopsy program utilizing a 2.4 mm cryoprobe in can achieve a high diagnostic yield with a favorable safety profile. Published by Elsevier Ltd.
Authors: Catherine L Oberg; Ryan P Lau; Erik E Folch; Tao He; Reza Ronaghi; Irawan Susanto; Colleen Channick; Rodrigo Garcia Tome; Scott Oh Journal: Lung Date: 2022-10-10 Impact factor: 3.777